Eculizumab is currently approved for treatment of aHUS and recently for neuromyelitis optica spectrum disorder (NMOSD) with aquaporin‐4 antibodies (AQP4‐IgG). The gene discussed is AQP4; the disease is atypical hemolytic-uremic syndrome.